scout
|Videos|July 2, 2015

Avelumab in Patients With Relapsed or Recurrent Ovarian Cancer

Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME